These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 16401659)

  • 21. The treatment of urinary incontinence with Duloxetine.
    Basu M; Duckett J
    J Obstet Gynaecol; 2008 Feb; 28(2):166-9. PubMed ID: 18393011
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Dual acting reuptake inhibitors in the treatment of depression and pain].
    Hajak G
    Dtsch Med Wochenschr; 2006 Dec; 131 Suppl 8():S280-3. PubMed ID: 17139587
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Successful duloxetine use to prevent venlafaxine withdrawal symptoms.
    Hsiao MC; Liu CY
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Feb; 32(2):576. PubMed ID: 17889418
    [No Abstract]   [Full Text] [Related]  

  • 24. Duloxetine and other antidepressants in the treatment of patients with fibromyalgia.
    Arnold LM
    Pain Med; 2007 Sep; 8 Suppl 2():S63-74. PubMed ID: 17714117
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Duloxetine: a new serotonin/noradrenaline reuptake inhibitor for the treatment of depression.
    Rabasseda X
    Drugs Today (Barc); 2004 Sep; 40(9):773-90. PubMed ID: 15538550
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Duloxetine is effective in treating depression in multiple sclerosis patients: an open-label multicenter study.
    Solaro C; Bergamaschi R; Rezzani C; Mueller M; Trabucco E; Bargiggia V; Dematteis F; Mattioda A; Cimino V; Restivo D; Patti F; Cavalla P
    Clin Neuropharmacol; 2013; 36(4):114-6. PubMed ID: 23783007
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Escitalopram and duloxetine in the treatment of major depressive disorder: a pooled analysis of two trials.
    Lam RW; Andersen HF; Wade AG
    Int Clin Psychopharmacol; 2008 Jul; 23(4):181-7. PubMed ID: 18545055
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment benefits of duloxetine in major depressive disorder as assessed by number needed to treat.
    Cookson J; Gilaberte I; Desaiah D; Kajdasz DK
    Int Clin Psychopharmacol; 2006 Sep; 21(5):267-73. PubMed ID: 16877897
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and tolerability of duloxetine, a novel dual reuptake inhibitor, in the treatment of major depressive disorder.
    Schatzberg AF
    J Clin Psychiatry; 2003; 64 Suppl 13():30-7. PubMed ID: 14552654
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Evidence-based recommendations for the treatment of fibromyalgia syndrome].
    Harten P; Genth E
    Z Rheumatol; 2010 Jul; 69(5):457-60. PubMed ID: 18836732
    [No Abstract]   [Full Text] [Related]  

  • 31. Safety and tolerability of duloxetine in elderly patients with major depressive disorder: a pooled analysis of two placebo-controlled studies.
    Oakes TM; Katona C; Liu P; Robinson M; Raskin J; Greist JH
    Int Clin Psychopharmacol; 2013 Jan; 28(1):1-11. PubMed ID: 23138680
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Improvement with duloxetine in an adult ADHD patient.
    Tourjman SV; Bilodeau M
    J Atten Disord; 2009 Jul; 13(1):95-6. PubMed ID: 19359667
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Duloxetine: mechanism of action at the lower urinary tract and Onuf's nucleus.
    Jost W; Marsalek P
    Clin Auton Res; 2004 Aug; 14(4):220-7. PubMed ID: 15316838
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serotonin-norepinephrine reuptake inhibitor treatment for tinnitus and depression.
    Chang JP; Wu CC
    J Clin Psychopharmacol; 2012 Oct; 32(5):729. PubMed ID: 22926618
    [No Abstract]   [Full Text] [Related]  

  • 35. Analgesic effects of serotonergic, noradrenergic or dual reuptake inhibitors in the carrageenan test in rats: evidence for synergism between serotonergic and noradrenergic reuptake inhibition.
    Jones CK; Eastwood BJ; Need AB; Shannon HE
    Neuropharmacology; 2006 Dec; 51(7-8):1172-80. PubMed ID: 17045620
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of serotonin norepinephrine reuptake inhibitors in the treatment of attention-deficit hyperactivity disorder in pediatrics.
    Park P; Caballero J; Omidian H
    Ann Pharmacother; 2014 Jan; 48(1):86-92. PubMed ID: 24259607
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hyperprolactinemia and galactorrhea induced by serotonin and norepinephrine reuptake inhibiting antidepressants.
    Ashton AK; Longdon MC
    Am J Psychiatry; 2007 Jul; 164(7):1121-2. PubMed ID: 17606668
    [No Abstract]   [Full Text] [Related]  

  • 38. The use of selective serotonin reuptake inhibitors in eating disorders.
    Mayer LE; Walsh BT
    J Clin Psychiatry; 1998; 59 Suppl 15():28-34. PubMed ID: 9786308
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [A challenge].
    Krankenpfl J; 2005; 43(4-6):93. PubMed ID: 16171044
    [No Abstract]   [Full Text] [Related]  

  • 40. Duloxetine-modulating effects of brain structure in major depressive disorder with panic disorder.
    Lai CH
    J Clin Psychopharmacol; 2010 Feb; 30(1):88-9. PubMed ID: 20075662
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.